دورية أكاديمية

Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience.

التفاصيل البيبلوغرافية
العنوان: Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience.
المؤلفون: Ko, Dong‐Hwan I, Norriss, Andrew, Harrington, Christopher R, Robinson, Bridget A, James, Melissa L
المصدر: Journal of Medical Imaging & Radiation Oncology; Apr2015, Vol. 59 Issue 2, p243-247, 5p
مصطلحات موضوعية: RADIOTHERAPY, MEDICAL radiology, MASTECTOMY, BREAST cancer surgery, BREAST cancer patients
مصطلحات جغرافية: CHRISTCHURCH (N.Z.)
مستخلص: Introduction Although hypofractionated radiotherapy ( HFRT) has become an accepted option for whole-breast irradiation after breast-conserving surgery, there is limited evidence to support HFRT to the chest wall following mastectomy. We retrospectively analysed post-mastectomy patients treated with HFRT in Christchurch to determine whether HFRT yields acceptable efficacy and toxicity. Methods The Christchurch oncology database was used to identify breast cancer patients treated with adjuvant HFRT to the chest wall following a mastectomy between 2003 and 2008. Eligible post-mastectomy patients were treated with 40 Gy in 16 daily fractions. Treatment outcomes assessed included local recurrence-free survival, breast cancer survival, overall survival and acute toxicities. Results One hundred thirty-three patients were identified. The median follow-up period was 5.03 years. Three patients had a local recurrence as a first event, resulting in 5-year local recurrence-free survival of 97.6%. Five-year overall survival and 5-year breast cancer survival were 74.7% and 77.7%, respectively. The prospectively assessed acute toxicities were mostly grade 1. In particular, the incidence of grade 2 skin toxicity was 10.7%, and no patients experienced grade 3 skin toxicity. Conclusion The high local control rate with HFRT, combined with acceptable toxicity and the practical benefits of a shorter treatment time, supports its ongoing use in the eligible patient group. A randomised controlled trial would be necessary to more completely assess the acute and long-term toxicity of HFRT compared with standard fractionation. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Medical Imaging & Radiation Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:17549477
DOI:10.1111/1754-9485.12242